D.B. Root & Company LLC Sells 2,155 Shares of Johnson & Johnson $JNJ

D.B. Root & Company LLC cut its holdings in Johnson & Johnson (NYSE:JNJ) by 41.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,046 shares of the company’s stock after selling 2,155 shares during the quarter. D.B. Root & Company LLC’s holdings in Johnson & Johnson were worth $465,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Global Strategic Investment Solutions LLC boosted its position in shares of Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after purchasing an additional 65 shares in the last quarter. JSF Financial LLC boosted its position in shares of Johnson & Johnson by 2.2% during the second quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock worth $457,000 after purchasing an additional 65 shares in the last quarter. Elios Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its position in shares of Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after purchasing an additional 67 shares in the last quarter. Finally, MBA Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock worth $921,000 after purchasing an additional 68 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.4%

Johnson & Johnson stock opened at $188.95 on Wednesday. The firm has a market capitalization of $455.06 billion, a PE ratio of 20.21, a P/E/G ratio of 2.40 and a beta of 0.40. The company’s 50-day moving average is $177.04 and its 200-day moving average is $163.18. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.92. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. Johnson & Johnson’s payout ratio is presently 55.61%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. HSBC boosted their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday. Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $189.88.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.